Viridian Therapeutics (NASDAQ: VRDN)
Viridian Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Viridian Therapeutics Company Info
Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.
News & Analysis
Why Shares of Viridian Therapeutics Are Falling Tuesday
The company announced preliminary trial results for its lead therapy.
Why These 2 Nasdaq Biotech Stocks Fell Hard Tuesday Morning
Broader markets seemed likely to start out on a positive note despite these two outliers.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.